Erschienen in:
30.07.2018 | Translational Research and Biomarkers
Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer
verfasst von:
Sook Kyung Do, MS, Ji Yun Jeong, MD, Shin Yup Lee, MD, PhD, Jin Eun Choi, PhD, Mi Jeong Hong, PhD, Hyo-Gyoung Kang, PhD, Won Kee Lee, PhD, Yangki Seok, MD, PhD, Eung Bae Lee, MD, PhD, Kyung Min Shin, MD, Seung Soo Yoo, MD, PhD, Jaehee Lee, MD, PhD, Seung Ick Cha, MD, PhD, Chang Ho Kim, MD, PhD, Michael L. Neugent, MS, Justin Goodwin, MS, Jung-whan Kim, DVM, PhD, Jae Yong Park, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 11/2018
Einloggen, um Zugang zu erhalten
Abstract
Background
This study was conducted to investigate whether polymorphisms of glucose transporter 1 (GLUT1) gene are associated with the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection.
Methods
Five single nucleotide polymorphisms (SNPs) in GLUT1 were investigated in a total of 354 patients with NSCLC who underwent curative surgery. The association of the SNPs with patients’ survival was analyzed.
Results
Among the five SNPs investigated, two SNPs (GLUT1 rs3820589T > A and rs4658G > C) were significantly associated with OS in multivariate analyses. GLUT1 rs3820589T > A was associated with significantly better OS (adjusted hazard ratio [aHR] = 0.57, 95% confidence interval [CI] = 0.34–0.94, P = 0.03, under dominant model), and rs4658G > C was associated with significantly worse OS (aHR = 1.91, 95% CI = 1.09–3.33, P = 0.02, under recessive model). In the stratified analysis by tumor histology, the effect of these SNPs on OS was only significant in squamous cell carcinoma but not in adenocarcinoma. When the two SNPs were combined, OS decreased as the number of bad genotypes increased (Ptrend = 4 × 10−3).
Conclusions
This study suggests that genetic variation in GLUT1 may be useful in predicting survival of patients with early stage NSCLC.